2025 Cohort
Introduction
We’ve all got to start somewhere. We recognise that one of the best ways to ensure the continued growth and success of the UK life science sector is to provide an encouraging and supportive environment within which our very early-stage ventures can stress test their science and business ideas. A good cohort isn’t just about great science – it’s about people, making connections and a shared bond centred around wanting to make a difference. For this reason, our cohorts are always a diverse group with a range of different life and work experience. The 2025 cohort was no exception! Meet them here…
AAB Therapeutics
AAB Therapeutics is developing engineered extracellular vesicles (EVs) as a scalable, cost-effective alternative to CAR T-cell therapy for B-cell lymphoma. These EVs selectively target B-cells and deliver therapeutic mRNA cargo, offering the potential of a safer, off-the-shelf treatment.
AmnioCam
AmnioCam, emerging from research at the Babraham Institute, AmnioCam is pioneering a stem cell-based alternative to placental donor-harvested amniotic cells. The technology enables a cost-effective, uniform and unlimited supply of amniotic cells for chronic wound healing, addressing clinical needs in conditions such as diabetic foot ulcers and pressure sores.
Cyclana Bio
Cyclana bio’s interdisciplinary team merges computational and tissue-level biology to discover a cure for endometriosis. By harnessing the breadth of information available each month from menstrual fluid, the team is building data-driven knowledge and lab-based tissue models of disease to identify novel treatments, focussing especially on the dark matter of tissue: the extracellular matrix.
MabGalaxy
MabGalaxy is accelerating the discovery of new antibody medicines by combining the power of the natural immune system with artificial intelligence. This integrated approach significantly shortens the timeline from early research to preclinical drug candidates, enabling innovative treatments to reach patients faster.
Sysora Health
Sysora Health is developing a targeted antibacterial gel to destroy Porphyromonas gingivalis whilst preserving beneficial oral bacteria. P. gingivalis is a key driver of severe gum disease, stimulating inflammation and exacerbating chronic diseases such as diabetes and cardiovascular disease.